SCHEMBL22684100

SCHEMBL22684100

O=C(c1ccncc1Br)N1CC(F)(F)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.41
PDE10A Q9Y233 1/20 0.38
PIK3C3 Q8NEB9 2/20 0.37
RIPK1 Q13546 5/20 0.37
PDE4B Q07343 2/20 0.37
PDE4D Q08499 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4C Q08493 1/20 0.37
RBP4 P02753 1/20 0.36
SPR P35270 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
PLAT P00750 1/20 0.35
SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684241 0.84 GAA (0.47) GAAPDE10ARBP4MEN1KMT2A
SCHEMBL15402054 0.82 KDM4E (0.51) GAAPDE10APIK3C3PDE4BPDE4D
SCHEMBL22683855 0.80 GAA (0.44) GAAPDE10ARBP4POLBMEN1
SCHEMBL10272980 0.80 GAA (0.47) GAAPOLBMEN1KMT2A
SCHEMBL3749424 0.79 KDM4E (0.40) GAAPDE10APIK3C3PDE4BPDE4D
SCHEMBL15758459 0.78 GAA (0.65) GAAPOLBMEN1KMT2A
SCHEMBL30431543 0.75 CYP3A4 (0.51) GAA
SCHEMBL30432531 0.73 SPR (0.44) PDE10APIK3C3RIPK1PDE4BPDE4D
SCHEMBL22684119 0.73 SPR (0.44) PDE10APIK3C3RIPK1PDE4BPDE4D
SCHEMBL22702046 0.72 POLB (0.56) GAAPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
EP-3740478-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R GAA 3670/4885PDE10A 3558/4885PIK3C3 379/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R GAA 3670/4885PDE10A 3558/4885PIK3C3 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.